

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

grant a product specific waiver MHRA-101333-PIP01-24

Scope of the Application

Active Substance(s)

2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone monohydrate

Condition(s)

Treatment of Parkinson's disease

Pharmaceutical Form(s)

Film-coated tablet

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

UCB Pharma Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, UCB Pharma Limited submitted to the licensing authority on 01/02/2024 19:15 GMT an application for a Paediatric Investigation Plan

The procedure started on 06/08/2024 15:22 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to grant a product specific waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.



MHRA

10 South Colonnade Canary Wharf London E14 4PU United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-101333-PIP01-24

Of 02/09/2024 13:29 BST

On the adopted decision for 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone monohydrate (MHRA-101333-PIP01-24) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Granting a waiver in all age groups for the listed condition(s)

This decision applies to a Paediatric Investigation Plan for 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone monohydrate, Film-coated tablet , ORAL USE .

This decision is addressed to UCB Pharma Limited, 208 Bath Road, Slough, Berkshire, Slough, UNITED KINGDOM, SL1 3WE

ANNEX I

1. Waiver

1.1 Condition:

Treatment of Parkinson's disease The waiver applies / applied to: Paediatric Subset(s): All subsets of the paediatric population from birth to less than 18 years of age Pharmaceutical form(s): Film-coated tablet Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Not Applicable

Not Applicable			

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

Not Applicable		

2.4 Pharmaceutical Form(s):

Not Applicable		

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not Applicable
Non-Clinical Studies	0	Not Applicable
Clinical Studies	0	Not Applicable
Extrapolation, Modeling &	0	Not Applicable
Simulation Studies		
Other Studies	0	Not Applicable
Other Measures	0	Not Applicable

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	
Date of completion of the paediatric investigation plan:	
Deferral of one or more studies contained in	
the paediatric investigation plan:	